Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Gains from Sales and Divestitures (2022 - 2025)

Axsome Therapeutics' Gains from Sales and Divestitures history spans 4 years, with the latest figure at $321470.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 20.05% year-over-year to $321470.0; the TTM value through Dec 2025 reached $321470.0, up 20.05%, while the annual FY2025 figure was $321470.0, 20.05% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $321470.0 at Axsome Therapeutics, up from $295835.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $321470.0 in Q4 2025 and bottomed at $61581.0 in Q1 2022.
  • The 4-year median for Gains from Sales and Divestitures is $202457.5 (2023), against an average of $190608.1.
  • The largest annual shift saw Gains from Sales and Divestitures soared 161.15% in 2023 before it grew 16.06% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $81639.0 in 2022, then skyrocketed by 138.15% to $194425.0 in 2023, then surged by 37.73% to $267779.0 in 2024, then increased by 20.05% to $321470.0 in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Gains from Sales and Divestitures are $321470.0 (Q4 2025), $295835.0 (Q3 2025), and $268394.0 (Q2 2025).